Medtronic’s Q3 2026 revenues reach $9bn on strong PFA demand

Medtronic has reported total revenue of $9bn in Q3 of fiscal year 2026 (FY26), led by the strongest growth the company has recorded in its cardiovascular portfolio in the past decade. With revenue for the quarter indicative of a year-over-year (YoY) rise of 8.7%, Medtronic has reiterated FY26 revenue growth on an organic basis of approximately 5.5%, with earnings anticipated to fall in the $5.62-$5.66 range. In a research note, William Blair analyst Brandon Vasquez highlighted that fiscal third-quarter ...